why choose us

300×250 Ad Slot

Research Article: GBP Expression Predicted Prognosis of Immune Checkpoint Inhibitors in Small Cell Lung Cancer and Correlated with Tumor Immune Microenvironment

Date Published: 2023-09-20

Abstract:
Lung cancer continues to have the highest morbidity and mortality in the world compared with other types of tumors. Specifically, small cell lung cancer (SCLC) is a highly malignant neuroendocrine tumor, accounting for ~% of all lung cancers. Even if successfully treated, SCLC patients are prone to relapse. Thus, traditional combination therapy tends to have a poor outcome for patients with advanced SCLC, resulting in an average overall survival (OS) time of about months. More than % of SCLC patients exhibit distant metastasis at the time of diagnosis, which has historically restricted the research and treatment options related to tumor occurrence and development. Consequently, the -year survival rate of SCLC patients has remained fundamentally unchanged for more than years. However, with the recent improvements in the understanding of immune checkpoint inhibitors (ICIs), including programmed cell death protein- (PD-) inhibitor and programmed death ligand- (PD-L) inhibitor, the prognosis of SCLC patients is likely to improve.

Introduction:
Lung cancer continues to have the highest morbidity and mortality in the world compared with other types of tumors. Specifically, small cell lung cancer (SCLC) is a highly malignant neuroendocrine tumor, accounting for ~% of all lung cancers. Even if successfully treated, SCLC patients are prone to relapse. Thus, traditional combination therapy tends to have a poor outcome for patients with advanced SCLC, resulting in an average overall survival (OS) time of about months. More than % of SCLC patients exhibit…

Read more

300×250 Ad Slot